Price
No data yet.
Social Signal Score
Analyst Ratings
27 analystsRevenue
$15.23B+65.99%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Belén Garijo López
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 76,493
- Beta
- 0.28
- Country
- FR
- Piotroski score
- 8 / 9 (Strong)
- Altman Z-score
- 1.76
Financials
Revenue
$15.23B+66.0%Net Income
$3.02B+282.4%EBITDA
$4.98B+48.7%Free Cash Flow
$3.24B-9.7%EPS (diluted)
$1.26+306.5%Shares Outstanding (diluted)
2.40B-6.5%Operating Expenses
$4.34BCash & Debt
$5.97BReturn of Capital
$18.00MDividend per Share
$2.42Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $46.72B | $7.81B | $3.20 |
| 2024 | $44.29B | $5.56B | $2.19 |
| 2023 | $41.62B | $5.40B | $2.15 |
| 2022 | $40.56B | $8.37B | $3.19 |
| 2021 | $39.17B | $6.22B | $2.49 |
| 2020 | $37.37B | $12.29B | $4.91 |
| 2019 | $37.63B | $2.75B | $1.14 |
| 2018 | $35.68B | $4.31B | $1.73 |
| 2017 | $36.22B | $8.42B | $1.50 |
| 2016 | $34.70B | $4.71B | $1.83 |
| 2015 | $34.86B | $4.29B | $1.64 |
| 2014 | $32.00B | $4.39B | $1.67 |
| 2013 | $31.29B | $3.72B | $1.41 |
| 2012 | $35.96B | $4.89B | $1.85 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from SNY's reported EPS growth of 4.3% a year over 13 years.
- EPS in 5 years
- $3.95
- Implied price
- $51.36
- Return from $46.15
- 2.2% a year
To earn 15.0% a year on these assumptions you'd need to buy at $25.54 — -44.7% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 9 | 11 | 13 | 15 | 17 |
|---|---|---|---|---|---|
| -5.7% | -14.2% | -10.7% | -7.6% | -4.9% | -2.5% |
| -0.7% | -9.6% | -5.9% | -2.7% | 0.1% | 2.6% |
| 4.3% | -5.1% | -1.2% | 2.2% | 5.1% | 7.8% |
| 9.3% | -0.5% | 3.5% | 7.1% | 10.2% | 13.0% |
| 14.3% | 4.0% | 8.3% | 12.0% | 15.2% | 18.1% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50+150.00%Social Signal Score
Mentions (41)
- Newsmarketbeat.com·2d ago·Neutral
Sanofi Maps Vaccine Pipeline With Flu-COVID and Pneumococcal Trial Results Ahead Sanofi NASDAQ: SNY is advancing a slate of vaccine candidates targeting respiratory infections, pneumococcal disease and acne, with several clinical readouts expected over the next 18 months, according to its head of vaccines research and development.
View source ↗ - Newscnbc.com·3d ago·Negative
As Sanofi's Pompe drug shortage drags on, some patients struggle to access treatments A shortage of Sanofi's Pompe disease drugs has lasted for more than three months, forcing some patients to miss critical infusions. Sanofi says the shortage is due to manufacturing issues at its facility in Ireland.
View source ↗ - Newszacks.com·3d ago·Positive
SNY Wins FDA Approval for Infilbray in Type 3 Gaucher Disease Sanofi gains FDA approval for Infilbray, the first U.S. therapy targeting progressive neurological symptoms of type 3 Gaucher disease.
View source ↗ - Newsbusinesswire.com·3d ago·Neutral
Jacobs selected by Sanofi to deliver new insulin manufacturing facility in Germany DALLAS--(BUSINESS WIRE)-- #OurJacobs--Jacobs selected by Sanofi as the EPCM partner for a new insulin manufacturing facility in Frankfurt, Germany.
View source ↗ - Newsglobenewswire.com·3d ago·Neutral
Press Release: Sanofi's next-generation rabies vaccine, VaxRabeo, approved in the EU for all ages Sanofi's next-generation rabies vaccine, VaxRabeo, approved in the EU for all ages Paris, November 19, 2026. Sanofi announced today that the European Commission has approved VaxRabeo (rabies virus inactivated strain Wistar) for pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) against rabies for all age groups.
View source ↗ - Newsglobenewswire.com·4d ago·Neutral
Press Release: Sanofi's Infilbray approved in the US as the first medicine to treat neurological manifestations of Type 3 Gaucher disease Sanofi's Infilbray approved in the US as the first medicine to treat neurological manifestations of Type 3 Gaucher disease
View source ↗ - Newsreuters.com·4d ago·Negative
US FDA approves Sanofi's genetic disorder drug US FDA approves Sanofi's genetic disorder drug
View source ↗ - Newsglobenewswire.com·19d ago·Neutral
Nurix Therapeutics Announces Sanofi's Decision to Discontinue Development of STAT6 Degrader SAR448272 BRISBANE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines, today announced that Sanofi notified Nurix of its decision to discontinue the Phase 1 first-in-human clinical trial of SAR448272, an oral STAT6 degrader, and to terminate the SAR448272 program.
View source ↗ - Newszacks.com·19d ago·Negative
Recursion's Q3 Earnings Beat Estimates on Sanofi Milestone Revenues RXRX Q3 revenues surge 258.5%, beating estimates as a $10 million Sanofi milestone payment boosts results and advances its drug pipeline.
View source ↗ - Newsmarketbeat.com·23d ago·Neutral
Sanofi Q3 Earnings Call Highlights Sanofi NASDAQ: SNY reported third-quarter 2026 sales growth of 14.3% at constant exchange rates, supported by continued demand for Dupixent, recently launched medicines and growth in rare diseases. The company also raised its full-year sales and business EPS outlook while outlining a strategy focused on immunology, rare diseases and vaccines.
View source ↗ - News247wallst.com·23d ago·Neutral
Regeneron Surges 12% as Sanofi Dupixent Windfall and Eylea HD Power Earnings Beat; Moderna Slides 2%, Merck Edges Higher, Pfizer Ticks Up A strong third quarter has made Regeneron Pharmaceuticals (NASDAQ:REGN | REGN Price Prediction) a standout healthcare gainer on a day when tech stocks are selling off. In morning trading, Regeneron stock has climbed to $919.58, up 12%.
View source ↗ - Newszacks.com·23d ago·Positive
Sanofi Q3 Earnings & Sales Beat, 2026 View Up, Shares Rise SNY beats Q3 earnings and sales estimates as Dupixent drives growth and the company raises its 2026 outlook for sales and business EPS.
View source ↗ - Newswsj.com·23d ago·Negative
Sanofi CEO Sets Sights on Deals to Drive Turnaround The French drugmaker is moving to fill its medicine pipeline to prepare for the looming patent expiration of its bestselling product, Dupixent.
View source ↗ - News247wallst.com·27d ago·Negative
Regeneron's Billion-Dollar Catalyst Flying Under Wall Street's Radar Ahead of Oct. 30 Earnings Regeneron (NASDAQ:REGN | REGN Price Prediction) reports third-quarter results on Oct. 30. Regeneron books its full share of Dupixent profits from Sanofi (NASDAQ:SNY) for the first time this quarter.
View source ↗ - Newsseekingalpha.com·27d ago·Positive
Sanofi: An Alluring And Balanced Mix Of Yield And Growth Sanofi has increased its dividend for 31 consecutive years. It's only because this is not an American company in the S&P 500 that it's not a dividend aristocrat. Sanofi increased its revenue from €34.7 billion in FY 2016 to €43.6 billion in FY 2025. That's a compound annual growth rate of 2.6%. Sanofi has a great financial position. The long-term debt/equity ratio is 0.2, while the interest coverage ratio is 11.
View source ↗ - Newsseekingalpha.com·33d ago·Positive
Sanofi: Why The Market Seems To Be Overpricing Pipeline Risk Sanofi is deeply undervalued, trading at 8.4x P/E despite AA rating, robust balance sheet, and a 5.8% dividend yield. I see SNY pipeline risks as overstated; Dupixent's expansion and multiple smaller launches provide solid growth through 2028E. Even with no new blockbusters, SNY offers 15%+ annualized upside at normalized EPS and historical multiples, supporting a strong value thesis.
View source ↗ - Newsglobenewswire.com·34d ago·Neutral
Enable Injections Announces Approval in Japan for CirCLIQ® Injector based on enFuse® On-Body Delivery System Sanofi's CirCLIQ® Injector, developed using enFuse technology, has been approved to administer Sarclisa subcutaneous formulation, in combination with approved standard-of-care regimens, for patients with multiple myeloma Sanofi's CirCLIQ® Injector, developed using enFuse technology, has been approved to administer Sarclisa subcutaneous formulation, in combination with approved standard-of
View source ↗ - Newsglobenewswire.com·34d ago·Neutral
Press Release: Sanofi breaks ground on new state-of-the-art insulin manufacturing facility in Germany Sanofi breaks ground on new state-of-the-art insulin manufacturing facility in Germany Paris and Frankfurt, October 19, 2 026. Sanofi today broke ground on a new state-of-the-art insulin manufacturing facility at its BioCampus in Frankfurt, Germany.
View source ↗ - Newsglobenewswire.com·38d ago·Neutral
Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration Potential first-in-class dual targeting inhibitor oral small molecule to enter Sanofi's development pipeline, with phase 1 clinical study currently planned to begin in 2027 Potential first-in-class dual targeting inhibitor oral small molecule to enter Sanofi's development pipeline, with phase 1 clinical study currently planned to begin in 2027
View source ↗ - Newszacks.com·39d ago·Positive
Which Pharma Stock Looks More Attractive: Sanofi or AbbVie? Sanofi's upgraded 2026 outlook, Dupixent growth and attractive valuation give it an edge over AbbVie, despite pipeline setbacks and vaccine sales challenges.
View source ↗ - Newswsj.com·39d ago·Neutral
EU Accepts Sanofi's Concessions to Settle Antitrust Probe Over Vaccine Marketing Sanofi's offer to rectify the potential effects of its past messages on a rival flu shot awould address concerns, the bloc's executive arm said.
View source ↗ - Newsglobenewswire.com·47d ago·Negative
Press Release : Availability of the aide-mémoire for Q3 2026 results Availability of the aide-mémoire for Q3 2026 results Paris, France – October 6, 2026. Sanofi announced today the availability of the aide-mémoire for Q3 2026 results on the "Investors" page of sanofi.com: Third quarter 2026 results Prepared each quarter, this document is intended to support financial modelling of the quarterly results.
View source ↗ - Newsbusinesswire.com·48d ago·Negative
As First Dupixent MDL Hearing Opens, Weitz & Luxenberg Points to Sanofi's Own Words on a Cancer That Hides Behind Eczema NEW YORK--(BUSINESS WIRE)--Weitz & Luxenberg, which represents more people in the Dupixent litigation than any other firm, appeared this past Friday at the first hearing in the federal multidistrict litigation over allegations that Dupixent (dupilumab) can cause, accelerate or unmask cutaneous T-cell lymphoma (CTCL). Judge Zahid N. Quraishi of the U.S. District Court for the D
View source ↗ - Newszacks.com·51d ago·Positive
Sanofi, Regeneron Expand Immunology Alliance With New Antibodies SNY and REGN expand their longstanding alliance to four new antibodies targeting type II inflammation, with billions in potential payments.
View source ↗ - Newsseekingalpha.com·52d ago·Neutral
…The deal grants REGN $1B upfront and up to $7B in milestones, with a 50:50 global profit split for new assets, enhancing alignment and commercial potential. REGN and SNY now have several shots on goal to address Dupixent loss-of-exclusivity and emerging long-acting competitors, with key assets potentially launching from 2030 onward.
View source ↗ - Newsmarketbeat.com·52d ago·Positive
Regeneron, Sanofi Expand Alliance in Deal Worth Up to $8 Billion Regeneron Pharmaceuticals NASDAQ: REGN and Sanofi said they are expanding their long-running collaboration to develop and commercialize next-generation medicines for type 2 inflammatory diseases, adding four Regeneron-originated antibody programs and establishing a new equal-sharing economic framework for the assets.
View source ↗ - Newsmarketbeat.com·52d ago·Neutral
Sanofi, Regeneron Expand DUPIXENT Alliance in Deal Worth Up to €8 Billion Regeneron and Sanofi NASDAQ: SNY announced an expanded collaboration focused on developing next-generation medicines for type 2 inflammatory diseases, extending an alliance that has produced the blockbuster therapy DUPIXENT.
View source ↗ - Newswsj.com·52d ago·Negative
Sanofi, Regeneron to Expand Alliance in Deal Valued at Up to $8 Billion The companies will share development and commercialization costs as well as potential future profits from the new drugs, they said.
View source ↗ - Newsreuters.com·52d ago·Negative
Sanofi to pay Regeneron $1 billion upfront in expanded immunology deal French drugmaker Sanofi said on Thursday it would pay US partner Regeneron $1 billion upfront and up to $7 billion more in milestone payments to add four next-generation, long-acting immunology antibodies to the partnership behind their blockbuster eczema drug Dupixent.
View source ↗ - Newsglobenewswire.com·52d ago·Positive
Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies Sanofi and Regeneron expand global Alliance with multiple nex t-generation, long-acting immunology antibodies REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regeneron, is added to the Alliance, along with a long-acting IL-4xIL-13 bispecific and two other long-acting pre-clinical antibodies from Regeneron Regeneron to receive $1 b
View source ↗ - Newsglobenewswire.com·52d ago·Positive
Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regeneron, is added to the alliance, along with a long-acting IL-4xIL-13 bispecific and two other long-acting preclinical antibodies from Regeneron
View source ↗ - Newszacks.com·58d ago·Negative
Sanofi's New Drugs Poised to Drive Growth Beyond Dupixent SNY's new drugs are gaining momentum, with Altuviiio, Ayvakit and Sarclisa poised to broaden growth beyond Dupixent.
View source ↗ - Newsmarketbeat.com·61d ago·Neutral
Sanofi Reviews Pipeline, Broadens Deal Hunt as It Rebuilds Research Engine Sanofi NASDAQ: SNY is reviewing its late-stage pipeline, broadening its business-development lens and working to rebuild early research output under new leadership, Chief Scientific Officer and Global Head of Research Mike Quigley said at a Bank of America event.
View source ↗ - Newsmarketbeat.com·63d ago·Negative
Sanofi Eyes €25B Dupixent Future, Expands M&A Hunt Ahead of Patent Loss Sanofi NASDAQ: SNY is prioritizing continued growth in Specialty Care while preparing for the loss of exclusivity of Dupixent in the early part of the next decade, according to Manuela Buxo, the company's executive vice president and head of Specialty Care.
View source ↗ - Newsseekingalpha.com·67d ago·Neutral
Sanofi: Stronger Launches And A New R&D Reset Keep The Re-Rating Case Alive Q2 strengthened earnings visibility, with higher guidance and continued Dupixent momentum supporting the 2026 outlook. Newer launches are scaling faster, giving Sanofi a clearer path toward a more diversified revenue base. The new R&D leadership adds credibility to pipeline prioritization and could improve capital allocation across internal and external innovation.
View source ↗ - Newsglobenewswire.com·69d ago·Neutral
Press Release: Sanofi and Cheplapharm to create new strategic partnership in mature medicines Sanofi and Cheplaphar m to create new strategic partnership i n mature medicines
View source ↗ - Newsglobenewswire.com·69d ago·Neutral
INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board Appointments strengthen rare-disease commercialization planning and strategic partnering capabilities as Ebstrocel™ advances toward potential commercialization BOCA RATON, Fla., Sept. 14, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced the appointments of R.
View source ↗ - Newszacks.com·86d ago·Negative
SNY Stock Trading Above 50- & 200-Day SMAs: Buy, Hold or Sell? Sanofi's stock trades above key moving averages as Dupixent and new drugs drive growth, while pipeline setbacks and vaccine weakness weigh.
View source ↗ - Newsfool.com·88d ago·Negative
Sanofi Boasts a Dividend Yield of 5.4%, Trades Below 9x Earnings, and Just Got an FDA Win. Are Income Investors Missing a Rare Opportunity? The FDA just approved the company's on-body injector for its blood cancer drug. Analysts see upside potential ahead for shares of the French pharmaceutical giant.
View source ↗ - Newsseekingalpha.com·90d ago·Neutral
Sanofi: Trump's Vaccine Policy Won't Break The Story On August 10, Trump signed Executive Order 14420. But I believe the pressure on Sanofi stock from Trump's Gold Standard Childhood Vaccine Recommendations will be temporary. Sanofi is trading at a significant discount, with a non-GAAP P/E ratio [FWD] of 9.2x, 53.2% below the sector median.
View source ↗ - Newsaccessnewswire.com·97d ago·Neutral
AimwellBio Secures Patented Behavioral AI Portfolio Backed by Oxford Science and Sanofi Pilot; Inventor Dr. Chris A. Jones Joins Board of Advisors Executed IP assignment brings a decade of technology, published research, and pharma-tested behavioral engagement capabilities into AimwellBio as the Company expands its scientific and medical advisory network MIAMI, FL / ACCESS Newswire / August 17, 2026 / AimwellBio (OTCID:AIMN) today announced the executed assignment of the Trustr intellectual prop
View source ↗
Earnings
Thu, Feb 4(in 2 months)
Consensus estimate $0.94 per share
Typical surprise +6.0% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Oct 30$2.04 vs $1.63beat
- Thu, Jul 30$1.21 vs $1.10beat
- Thu, Apr 23$1.10 vs $1.06beat
- Thu, Jan 29$0.89 vs $0.84beat
- Fri, Oct 24$1.70 vs $1.60beat
- Thu, Jul 31$0.90 vs $0.96miss
Estimates and results for SNY via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
- Alan Armstrongsenate · disclosed Jul 21, 2026 (113d later)Buy$15,001 - $50,000
- Lisa C. McClainhouse · MI09 · disclosed Oct 22, 2025 (41d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Sep 15, 2025 (42d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (57d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (22d later)Sell$1,001 - $15,000
- John Jameshouse · MI10 · disclosed Sep 6, 2024 (2d later)Sell$1,001 - $15,000
- John Jameshouse · MI10 · disclosed Sep 2, 2024 (297d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 8, 2023 (26d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 6, 2023 (28d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Sep 6, 2023 (26d later)Sell$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed Aug 13, 2023 (34d later)Sell$15,001 - $50,000
- Ro Khannahouse · CA17 · disclosed Jun 12, 2023 (31d later)Buy$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed Mar 20, 2023 (21d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Mar 8, 2023 (26d later)Buy$15,001 - $50,000
- Earl Blumenauerhouse · OR03 · disclosed Jul 6, 2022 (40d later)Buy$15,001 - $50,000
- John Henry Rutherfordhouse · FL04 · disclosed Apr 19, 2022 (34d later)Sell$1,001 - $15,000
- Greg Gianfortehouse · MT00 · disclosed Apr 7, 2020 (19d later)Buy$1,001 - $15,000
- Van Taylorhouse · TX03 · disclosed Apr 15, 2019 (21d later)Sell$15,001 - $50,000
- John Henry Rutherfordhouse · FL04 · disclosed Jan 2, 2019 (30d later)Sell$1,001 - $15,000
- John Henry Rutherfordhouse · FL04 · disclosed Aug 20, 2018 (405d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
